SHR-A1811, a next-generation ADC, exhibited remarkable outcomes in a phase I trial, particularly in patients with HER2-positive breast cancer previously treated with T-DM1 who were resistant to other HER2-targeted ADCs [104]. Here, ERBB2 is linked to breast carcinoma.